Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Payables (2016 - 2025)

Bioadaptives' Payables history spans 8 years, with the latest figure at $264821.0 for Q4 2025.

  • On a quarterly basis, Payables rose 25.18% to $264821.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $264821.0, a 25.18% increase, with the full-year FY2025 number at $264821.0, up 25.18% from a year prior.
  • Payables hit $264821.0 in Q4 2025 for Bioadaptives, down from $590068.0 in the prior quarter.
  • Over the last five years, Payables for BDPT hit a ceiling of $824132.0 in Q3 2022 and a floor of $127298.0 in Q2 2021.
  • Historically, Payables has averaged $498772.4 across 5 years, with a median of $497949.0 in 2024.
  • Biggest five-year swings in Payables: soared 355.68% in 2021 and later crashed 72.35% in 2024.
  • Tracing BDPT's Payables over 5 years: stood at $281465.0 in 2021, then soared by 181.28% to $791713.0 in 2022, then dropped by 3.34% to $765237.0 in 2023, then crashed by 72.35% to $211554.0 in 2024, then increased by 25.18% to $264821.0 in 2025.
  • Business Quant data shows Payables for BDPT at $264821.0 in Q4 2025, $590068.0 in Q3 2025, and $515081.0 in Q2 2025.